NCT00125515View on ClinicalTrials.gov

Memantine and Naltrexone Treatment for Opioid Dependence

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Opioid Dependence
Interventions
DRUG

Memantine

One arm receives 30 mg bid and the other arm receives receives 15mg bid

DRUG

Naltrexone

Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00125515 - Memantine and Naltrexone Treatment for Opioid Dependence | Biotech Hunter | Biotech Hunter